WomanCare Global Acquires Two New Oral Contraceptives

Posted on: November 4, 2010 by: Amy McNally

WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle®, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor®, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.

Both products were developed by ICON in partnership with a trusted generic manufacturer following an extensive in-depth qualityand technical assessment process undertaken by qualified experts in 2005. Both formulations are included in the WHO InteragencyList of Essential Medicines for Reproductive Health. ICON is the International Planned Parenthood Federation (IPPF) subsidiaryresponsible for commodity supply to IPPF member associations.

With this acquisition, WomanCare Global has global rights to Roselle® and Optinor® and a partner in making these branded products available to IPPF’s global network of Member Associations located in over 170 countries. WomanCare Global will also market these products to other public and private sector markets around the world using their established global supply chain and logistics network.

“This partnership with WomanCare Global is a significant step forward in expanding access to quality assured generic hormonalcontraceptives at competitive prices” said ICON’s General Manager, David Smith.

“WomanCare Global is excited about this important strategic alliance with a key partner” said WCG Chief Operating Officer SaundraPelletier. “The addition of these 2 new products to our global portfolio will make a significant difference to women around the worldwho deserve access to high-quality and affordable products. Roselle® and Optinor® will become important options for women.”

About WomanCare Global

WomanCare Global provides access to high-quality, innovative and affordable reproductive healthcare technologies forcontraception, fertility and pregnancy management. WomanCare Global’s mission is to expand the availability of these technologiesin both public and private sectors via an established global supply chain reaching over 80 countries and growing, with particularfocus on under-served markets in Africa, Asia and Latin America. WomanCare Global is a hybrid business model, combining the bestpractices of for-profit and not-for-profit entities. WomanCare Global has regulatory and quality departments that assure adherenceto regulatory requirements and global quality standards in addition to a comprehensive global sales, marketing, and distributionchannel. For more information about WomanCare Global, visit www.womancareglobal.com

Contact

Ellen Thomas
Corporate Communications
+1.919.442.2619

WomanCare Global Acquires Two New Oral Contraceptives